****Published February 2013****

# MarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042)

| | | |
|---|---|---|
| **Product Name** | : | **MarketVIEW:** Hepatitis C Virus (HCV) vaccines |
| **Description** | : | Global vaccine commercial opportunity assessment |
| **Contents** | : | Executive presentation + 2 forecast models |
| **Therapeutic Area** | : | Novel vaccines |
| **Publication date** | : | February 2013 |
| **Catalogue No** | : | VAMV042 |

## Background

Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to blood route where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk.

Pegylated interferons (PEG) and the non-specific antiviral ribavirin (R) have been the mainstay of HCV for many years but with lower success rates for patients infected with HCV genotype 1. Recently directly acting antivirals (DAAs) have been available such as Merck's boceprevir (Victrelis) and Vertex's telaprevir (Incivek/Incivo/Telavic). Triple therapy with Incivek and PegIFN/R improves SVR rates in treatment naïve and treatment-experienced patients compared to PegIFN/R alone. Beyond DAAs some companies are investigating HCV therapeutic (TX) and prophylatic (PX) vaccines.

This **MarketVIEW** product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western[1] markets until 2030. The models contain value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and immunological based treatments.

[1] US, Canada, Australia, UK, France, Italy, Germany, Spain, South Korea, Japan and Australia

# Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining Hepatitis C Virus (HCV) epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

**PRODUCT CONTENTS:**

**Published February 2013 (CAT No: VAMV042)**

****This product is composed of two forecast models and a summary presentation

Author's note
Executive Summary
Commercial model: major outputs
HCV TX vaccines: revenues ($m) by scenario
HCV TX vaccines: revenues ($m) by region
HCV PX vaccines: revenues ($m) by scenario
HCV PX vaccines: revenues ($m) by region
Chronically infected HCV population (000s), by region, 2010-2030
Treated patients (000s), any antiviral therapy (all genotypes), by region, 2010-2030
Treated patients (000s), any antiviral therapy (genotype 1), by region, 2010-2030
Commercial model: key assumptions
The role of HCV TX vaccine
The role of HCV PX vaccine
Key inputs: TX vaccine
Key inputs: PX vaccine
Overview of modelling strategy: TX vaccine
Pricing: TX vaccine
Overview of modelling strategy: PX vaccine
Pricing: PX vaccine
Epidemiology inputs: HCV prevalence
Epidemiology inputs: HCV populations by genotype
Epidemiology inputs: Estimated HCV populations by genotype, 2010
Epidemiology inputs: Injecting drug users
Epidemiology inputs: Estimated treatment rates (% of chronically infected HCV population)
HCV epidemiology summary
US: epidemiology
Europe: epidemiology
Canada: epidemiology
Japan, South Korea, Australia: epidemiology
HCV genotype distribution
Current HCV treatments – review of latest clinical data
Future HCV therapies
HCV vaccine pipeline
Okairos (TerCvax and ProCvax)


Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

**Continued.....**



**PAGES: ~75 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand model TX vaccine (MS Excel-based)**

**Continued.....**

**Worksheets = 40 interconnected**

**Contents – Vaccine demand model PX vaccine (MS Excel-based)**



**Worksheets = 40 interconnected**

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- o USD **$9995.00**/ GBP **£6245.00**[#] (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
*# - indicative prevailing rate will be applied on date of transaction*

**HOW TO ORDER:**

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

## BIBLIOGRAPHY


1. New agents for Hepatitis C: triple therapy/twice as good/one big bill. Available from: www.eugenegi.com/assets/uploads/EGI_newsletter_Oct11.pdf. Accessed: January 2013
2. HPA. Shooting Up. Infections among people who inject drugs in the UK 2011. An update: November 2012.
3. Krahn MD et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine. 2005 Feb 18;23(13):1549-58.
4. Armstrong GL et al. The prevalence of Hepatitis C virus infection in the United States, 1999 through 2002. Ann Int Med 2006;144:705-14.
5. US Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – United States, 2010. Available at: http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm. Accessed January 2013
6. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC; 2010.
7. Guadagnino V et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection. Dig Liver Dis. 2012 Nov 27. pii: S1590-8658(12)00412-4
8. Gramenzi A et al. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis. 2012 Aug;44(8):674-80.
9. Fabris P et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008 May-Jun;42(5):527-32.
10. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011.
11. Robert Koch Institute. Available at: http://www3.rki.de/SurvStat/. Accessed: January 2013
12. HPA. Hepatitis C in the UK: 2012 report. Available at: www.hpa.org.uk/. Accessed: January 2013
13. Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007. Available at: www.phac-aspc.gc.ca/sti-its-surv-epi/model/methods-eng.php. Accessed: January 2013.
14. Hepatitis C virus. Center for Hepatitis Research Center for Hepatitis and Immunology, International Medical Research Center, National Institute. Available at: http://www.kanen.ncgm.go.jp/forcomedi_hcv.html. Accessed: January 2013.
15. Suh DJ et al. Current status of hepatitis C virus infection in Korea. Intervirology. 2006;49(1-2):70-5.
16. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2012. Available at: http://www.kirby.unsw.edu.au/surveillance/2012-annual-surveillance-report-hiv-viral-hepatitis-stis. Accessed: January 2013.
17. Razali K et al. Modelling and calibration of the hepatitis C epidemic in Australia. Stat Methods Med Res. 2009 Jun;18(3):253-70.
18. Ghany, MG et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54: 1433–1444, 2011.
19. Vertex Pharmaceuticals Incorporated Management Discusses Q3 2012 Results - Earnings Call Transcript. November 1, 2012. Available at: http://seekingalpha.com. Accessed: January 2013.
20. Speciality Pharmacy news. Volume 9, Number 2. February 2012
21. Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek combination treatment): Drug Safety Communication - Serious Skin Reactions. Available at: http://www.fda.gov/. Accessed: January 2013.
22. BCG. The economic impact of hepatitis C in Australia. August 2012.
23. Abbott Laboratories HCV Program Update Conference November 12, 2012. Available from: http://seekingalpha.com. Accessed: January 2013.
24. Puoti M. et al. Top topics in HCV research arena. BMC Infect Dis. 2012 Nov 12;12 Suppl 2:S7.
25. Shiffman ML et al. GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In naïve HCV Genotype 1 Patients With IL28B Genotype T/T. The Liver Meeting 2012: American Association for the Study of Liver Diseases (AASLD) 63rd Annual Meeting. November 9 - 13, 2012; Boston, Massachusetts
26. Transgene. Corporate Presentation. JP Morgan Conference. San Francisco, CA, USA. January 2013
27. Micallef JM et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006 Jan;13(1):34-41.
28. Kershenobich D et al. Applying a system approach to forecast the total HCV-infected population size – model validation using US data. Liver Int 2011; 31(Suppl. 2): 4–17.
29. Volk ML et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009 Dec;50(6):1750-5
30. Lettmeier B et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol. 2008 Oct;49(4):528-36.

31. Worth the Wait? Should chronic hepatitis C patients be treated now or wait for promising therapies? AGA Perspectives. Vol. 8 No. 3. June/July 2012
32. Viral Hepatitis Managed Care Network . An audit of hepatitis C treatment activity and outcomes in Greater Glasgow and Clyde. October 2012. Available at: http://www.hepnet.scot.nhs.uk. Accessed: January 2013

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

**1.** This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

**2.** The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.

**3. Cancellation policy**. The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

**4. Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

**5.** Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.

**6.** If not purchased on line invoices are payable within **thirty days** of the invoice date.

**7.** All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.

**8.** The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

**9.** Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

**10.** Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

# About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com